Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety.
Maria ChaparroDiana AcostaCristina RodríguezFrancisco MesoneroMiren VicuñaManuel Barreiro-de AcostaAgnès Fernández-ClotetÁlvaro Hernández MartínezMaite ArroyoIsabel VeraAlexandra Ruiz-CerullaBeatriz SiciliaM José Cabello TapiaCarmen Muñoz VillafrancaJesús Castro-PoceiroJesús Martínez CadillaMónica Sierra-AusínJuan María Vázquez MorónRaquel Vicente LidónFernando BermejoVanesa RoyoMargalida CalafatCarlos González-MuñozaEduardo Leo CarnereroNoemi Manceñido MarcosLeyanira TorrealbaHoracio Alonso-GalánJosé Manuel BenítezYolanda Ber NietoM Teresa Diz-Lois PalomaresMaría José GarcíaJosé Fernando MuñozEdisa María Armesto GonzálezXavier CalvetAlejandro Hernández-CambaRosa Eva Madrigal DomínguezLuis MenchénJosé Lázaro Pérez CalleMarta PiquerasCarmen Dueñas SadornilBelén BotellaTeresa de Jesús Martínez-PérezLaura RamosMaría Carmen Rodríguez-GrauElena San MiguelJosé Luis Fernández ForcelledoPaola María Fradejas SalazarMarifé García-SepulcreAna GutiérrezJordina LlaóEva Sesé AbizandaMaia Boscá-WattsEduardo IyoAlma Keco-HuergaCarmen Martínez BonilElena Peña GonzálezPablo Pérez-GalindoPilar VarelaJavier P GisbertPublished in: The American journal of gastroenterology (2022)
Tofacitinib is effective both in the short and in the long-term in patients with UC. The safety profile is similar to that previously reported.
Keyphrases